Search clinical trials for: Peg-IFN-alfa-2b

Total 910 results

European Organisation for Research and Treatment...
NCIC Clinical Trials Group

Unknown

Adjuvant PEG Intron in Ulcerated Melanoma

Ulcerated Melanomas

France, Denmark, Italy, Belgium, Spain, United Kingdom, Netherlands, Austria, Germany, Poland, Switzerland, Portugal
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

P1101 in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
Tibotec BVBA

Completed

An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

Chronic Hepatitis C

France, Spain, Belgium, Germany, Austria, Netherlands
Hoffmann-La Roche

Completed

An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Belgium, France, Germany, Sweden, Switzerland, Turkey, Greece, Ireland, Taiwan, Estonia, Hungary, Italy, Romania, United Kingdom, Serbia, Morocco, Portugal, Saudi Arabia, Egypt, Pakistan, Lebanon, Macedonia, The Former Yugoslav Republic... and more
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C

Hepatitis C

Japan
Brooke Army Medical Center
T.R.U.E. Research Foundation

Completed

Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC

Hepatitis C

United States
ANRS, Emerging Infectious Diseases
Flamel Technologies

Unknown

Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4 (COAT IFN)

Chronic Hepatitis C

France
Merck Sharp & Dohme LLC

Completed

Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)

HIV Infections | Hepatitis C | Chronic Hepatitis C
Beijing 302 Hospital

Not yet recruiting

The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients

Chronic Hepatitis B

China
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059) (START 4)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)

Melanoma
University of Miami

Recruiting

Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma

Adult T-cell Leukemia-Lymphoma | ATLL

United States
University of Modena and Reggio Emilia
Merck Sharp & Dohme LLC

Unknown

Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC) (MEN_BOC)

Menopause | Chronic Hepatitis C

Italy
Ain Shams University
Schering-Plough; Tempus Labs; Fulbright; International Society for Infectious Diseases

Completed

Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4

Hepatitis C

Egypt
University of Michigan Rogel Cancer Center

Terminated

Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

United States
Merck Sharp & Dohme LLC

Terminated

Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed) (RE-CHUT)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)

Hepatitis C, Chronic
Northwestern University
National Cancer Institute (NCI)

Terminated

Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL

Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Institute of Liver and Biliary Sciences, India

Unknown

To Study the Efficacy of PEG-IFN Alpha in HBeAg Negative Chronic Hepatitis B Patients After Stopping Nucleotide Analogue Therapy.

Hepatitis B

India
National Cancer Institute (NCI)

Completed

Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

Metastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Regional Gastrointestinal Carcinoid Tumor

United States
The Wistar Institute
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Unknown

Reducing Proviral HIV DNA With Interferon-a (BEAT-HIV)

HIV/AIDS | HIV

United States
PharmaEssentia

Recruiting

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Polycythemia Vera

United States, Canada
Shanghai General Hospital, Shanghai Jiao Tong University...

Completed

Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

Recurrence | Hematological Neoplasms

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Merck Sharp & Dohme LLC

Terminated

Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)

Chronic Myelogenous Leukemia
Hoffmann-La Roche

Completed

Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

Hepatitis C, Chronic

United States
The University of Hong Kong

Recruiting

Ropeginterferon Alfa 2b for Early Myelofibrosis

Myelofibrosis | Primary Myelofibrosis, Prefibrotic Stage

Hong Kong
Biocad

Completed

An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients

Hepatitis | Hepatitis C | Hepatitis C/ Human Immunodeficiency Virus Coinfection

Russian Federation
Merck Sharp & Dohme LLC

Completed

Phase III PEG-Intron in HIV-infected Patients (Study P00738)

HIV Infections | AIDS
University of Pittsburgh
National Cancer Institute (NCI)

Completed

Study of PEG-Intron for Plexiform Neurofibromas

Plexiform Neurofibroma

United States
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED) (SPRINT-2)

Hepatitis C, Chronic
Tasly Tianjin Biopharmaceutical Co., Ltd.

Unknown

Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients

Hepatitis B Virus (HBV)

China
Azienda Ospedaliera V. Cervello

Unknown

Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies (IFNRIBAHE)

Hemoglobinopathies

Italy
Novartis
Human Genome Sciences Inc.

Completed

Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

Chronic Hepatitis C

Taiwan, Germany, Greece, Italy, Spain, United Kingdom, France, Canada, Australia, India, Poland, Thailand
Columbia University
Merck Sharp & Dohme LLC

Withdrawn

Boceprevir in End Stage Renal Disease (ESRD)

End Stage Renal Disease | Hepatitis C Infection
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
Eisai Inc.

Completed

A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors

Solid Tumors

Japan
PharmaEssentia Japan K.K.
PharmaEssentia

Completed

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects

Healthy Volunteers

Australia
PharmaEssentia

Completed

Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection

Chronic Hepatitis C Virus Infection

Korea, Republic of, Taiwan, China
Merck Sharp & Dohme LLC

Terminated

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)

Melanoma
Merck Sharp & Dohme LLC

Terminated

Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)

Hepatitis C, Chronic
St. Jude Children's Research Hospital
Schering-Plough

Active, not recruiting

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Malignant Melanoma

United States
PharmaEssentia

Not yet recruiting

Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Low-Risk Polycythemia Vera (PV)

Polycythemia Vera | Myeloproliferative Neoplasm
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Suspended

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Symptomatic COVID-19 Infection Laboratory-Confirmed

United States
Merck Sharp & Dohme LLC

Completed

Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514) (PROVIDE)

Hepatitis C, Chronic
Virginia Commonwealth University
Ortho Biotech, Inc.

Completed

Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection

Hepatitis C

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

Kidney Cancer

United States
Foundation for Liver Research

Completed

Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Treatment to Ncrease Sustained Response in CHB (PEGON)

Chronic Hepatitis B

Netherlands, China
Merck Sharp & Dohme LLC

Terminated

A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)

Malignant Melanoma

3

Subscribe